New Zealand links 26-year-old mans death to Pfizer COVID-19 vaccine – Reuters

A vial identified with the Pfizer-BioNTech coronavirus illness (COVID-19) vaccine is seen in this illustration picture taken March 19, 2021. REUTERS/Dado Ruvic/File PhotoRegister now for FREE unlimited access to Reuters.comRegisterSYDNEY, Dec 20 (Reuters) – New Zealand authorities on Monday stated they had linked a 26-year-old guys death to Pfizer Incs (PFE.N) COVID-19 vaccine after the person suffered myocarditis, an uncommon inflammation of the heart muscle, after taking his first dose.The death is New Zealands 2nd connected to a rare but known adverse effects from the vaccine after health authorities in August reported a woman had died after taking her doses. find out more “With the existing available details, the board has actually considered that the myocarditis was most likely due to vaccination in this person,” a COVID-19 Vaccine Independent Safety Monitoring Board said in a statement.Register now for FREE limitless access to Reuters.comRegisterThe guy, who died within 2 weeks of his first dose, had actually not looked for medical advice or treatment for his symptoms. Myocarditis is an inflammation of the heart muscle that can limit the organs capability to pump blood and can cause changes in heart beat rhythms.A Pfizer spokesperson said the business understood the report of the death in New Zealand, it monitored all reports of possible adverse occasions, and continued to think the benefit-risk profile for its vaccine was positive.New Zealands vaccine security board likewise said another two individuals, consisting of a 13-year-old, had died with possible myocarditis after taking their vaccinations. More details were required prior to linking the kids death to the vaccine, while the death of a guy in his 60s was not likely associated to the vaccine, it said.Despite the uncommon adverse effects, the vaccine safety board stated the advantages of vaccination greatly surpassed the risks.Register now free of charge limitless access to Reuters.comRegisterReporting by Renju Jose with extra reporting by Byron Kaye in Sydney
Editing by Robert BirselOur Standards: The Thomson Reuters Trust Principles.